Stockscreener 앱 받기
395.12
0.59%
-2.34
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Vertex to Participate in Upcoming September Investor Conferences - Business Wire
What's Wrong With Vertex Pharmaceuticals Stock? - MSN
Stock Analysis | Vertex Pharmaceuticals OutlookStrong Technicals and Mixed Analyst Sentiment - AInvest
Vertex Says 20,000 Prescriptions Filled for Non-Opioid Pain Drug - MSN
Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged - Yahoo Finance
Living life with cystic fibrosis: The Circle of Care grant - Vertex Pharmaceuticals
Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More - Seeking Alpha
Vertex Pharmaceuticals: Promising Growth with Successful Launch and Strong Pipeline - TipRanks
Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals - AInvest
Vertex Pharmaceuticals Inc: Financial Performance and Competitive Strengths - AInvest
Vertex Pharmaceuticals and Netflix: High-Conviction Growth Buys in a Volatile Market - AInvest
Vertex Pharma CEO Buys the Stock Dip - Barron's
Up and down the ladder: The latest comings and goings - statnews.com
Is This Beaten-Down Stock a Buy on the Dip? - AOL.com
Vertex Inc. Downgrade: Near-Term Growth Expectations Reset - AInvest
Joint Venture Receives $1B Refinancing for Vertex Pharmaceuticals Headquarters Facility in Boston - REBusinessOnline
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $430 From $530, Maintains Buy Rating - MarketScreener
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market - Yahoo Finance
The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals: Undervalued After Pain Drug Setbacks - AInvest
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX) - Seeking Alpha
Vertex HQ refinanced for $1 billion - The Business Journals
Vertex Pharmaceuticals Soars 3.44%—What’s Fueling This Biotech Breakout? - AInvest
Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), AMN Healthcare Services (AMN) - The Globe and Mail
Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point - Yahoo Finance
Vertex Pharmaceuticals: A Biotech Powerhouse Poised for Rebound After Oversold Correction - AInvest
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) (NASDAQ:VRTX) - Seeking Alpha
Goldman Sachs reiterates Buy rating on Vertex stock, citing diversification By Investing.com - Investing.com South Africa
Vertex Pharma announces new share buybacks worth up to $4B - MSN
The week in pharma: action, reaction and insight – week to August 8 - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN
Brazil’s Antitrust Watchdog Probes Soybean Traders Over Cartel Concerns - PYMNTS.com
Vertex unveils positive study data for CF triple-combination regimens; shares jump - FirstWord Pharma
KOL Views: Vertex's triplet data exceed expectations – implications for CF landscape - firstwordpharma.com
Vertex Analyst Rating Lowered by B of A Securities; VERX Stock Price Target Cut to $34.00 - AInvest
Moving Average Crossover Confirms Uptrend in Vertex Pharmaceuticals IncorporatedMarket Surge Signal for Swing Traders Triggered - beatles.ru
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com
Hedge Fund and Insider Trading News: Ken Griffin, DE Shaw, Bobby Jain, Jim Cramer, Rokos Capital Management, Point72 Asset Management, Vertex Pharmaceuticals Inc (VRTX), Galaxy Digital Inc (GLXY), and More - Insider Monkey
Vertex Pharmaceuticals shares fall 2.75% intraday after insider bought shares and $1.0 billion mortgage financing. - AInvest
Vertex Pharmaceuticals Plunges 2.69%—Is This the Bottom for Vertex Pharmaceuticals? - AInvest
Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener
Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com
RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener
Vertex Pharmaceuticals Executives Make Significant Stock Purchases - TradingView
$1B Deal: RMR Group Refinances Vertex Pharma's Boston HQ with 15-Year Lease Extension - Stock Titan
Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest
The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media
Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN
Vertex’s Journavx successor culled after falling short in Phase II trial - Clinical Trials Arena
1.45%
자본화:
|
볼륨(24시간):